Last reviewed · How we verify
Anti-human thymocyte immunoglobulin, equine (anti-human-thymocyte-immunoglobulin-equine)
Anti-human thymocyte immunoglobulin, equine (generic name: anti-human-thymocyte-immunoglobulin-equine) is a Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be drug developed by Pfizer Inc.. It is currently in preclinical development.
Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be
Anti-human thymocyte immunoglobulin, equine is used to treat conditions such as Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, and MDS. It is administered intravenously as part of a treatment regimen that may also include Cyclosporine.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | anti-human-thymocyte-immunoglobulin-equine |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be |
| Therapeutic area | Immunology |
| Phase | preclinical |
Mechanism of action
Anti-human thymocyte immunoglobulin is made by injecting human thymus cells into horses, stimulating the horse's immune system to produce antibodies against human T cells. These antibodies are then extracted and purified from horse serum. When given to patients, these antibodies circulate through the bloodstream and bind to T lymphocytes—the primary immune cells responsible for rejecting transplanted organs and attacking bone marrow in aplastic anemia. Once the antibodies attach to T cells, they mark them for destruction through multiple mechanisms. The body's own immune system recognizes these marked cells and eliminates them through several pathways, including complement activation (a system of proteins that destroy cells) and antibody-dependent cellular cytotoxicity (where other immune cells are recruited to kill the tagged T cells). This selective reduction in T cell numbers suppresses the overall immune response without completely shutting down immunity. Because this is derived from horse serum rather than rabbit serum, it may have different properties regarding how long it lasts in the body and how likely it is to cause serum sickness or other reactions. The equine formulation has been used clinically for decades to help prevent organ rejection after transplantation and to treat severe aplastic anemia, where the immune system has attacked the bone marrow's ability to produce blood cells.
Approved indications
Pipeline indications
- Aplastic Anemia — preclinical
Common side effects
Key clinical trials
- A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia (Phase 3)
- ATGAM General Investigation (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-human thymocyte immunoglobulin, equine CI brief — competitive landscape report
- Anti-human thymocyte immunoglobulin, equine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Anti-human thymocyte immunoglobulin, equine
What is Anti-human thymocyte immunoglobulin, equine?
How does Anti-human thymocyte immunoglobulin, equine work?
Who makes Anti-human thymocyte immunoglobulin, equine?
What is the generic name of Anti-human thymocyte immunoglobulin, equine?
What drug class is Anti-human thymocyte immunoglobulin, equine in?
What development phase is Anti-human thymocyte immunoglobulin, equine in?
Related
- Drug class: All Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing